Authors
Dieudonné Makaba Mvumbi, Thierry Lengu Bobanga, Jean-Marie Ntumba Kayembe, Georges Lelo Mvumbi, Hippolyte Nani-Tuma Situakibanza, Françoise Benoit-Vical, Pierrette Melin, Patrick De Mol, Marie-Pierre Hayette
Published in
PloS one. Volume 12. Issue 6. Pages e0179142. Epub Jun 08, 2017.
Abstract
Malaria is a major public health problem in the Democratic Republic of Congo. Despite progress achieved over the past decade in the fight against malaria, further efforts have to be done such as in the surveillance and the containment of Plasmodium falciparum resistant strains. We investigated resistance to artemisinin-based combination therapies currently in use in Democratic Republic of Congo by surveying molecular polymorphisms in three genes: pfcrt, pfmdr1 and pfk13 to explore possible emergence of amodiaquine, lumefantrine or artemisinin resistance in Democratic Republic of Congo. This study essentially revealed that resistance to chloroquine is still decreasing while polymorphism related to amodiaquine resistance seems to be not present in Democratic Republic of Congo, that three samples, located in the east of the country, harbor Pfmdr1 amplification and that none of the mutations found in South-East Asia correlated with artemisinine resistance have been found in Democratic Republic of Congo. But new mutations have been identified, especially the M476K, occurred in the same position that the M476I previously identified in the F32-ART strain, strongly resistant to artemisinine. Antimalarial first-line treatments currently in use in Democratic Republic of Congo are not associated with emergence of molecular markers of resistance.
PMID:
28594879
Bibliographic data and abstract were imported from PubMed on 05 Oct 2025.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 38
- Comments 0